These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31845296)

  • 1. Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium.
    Menezes BK; Alves IA; Staudt KJ; Beltrame BM; Venz L; Michelin L; Araujo BV; Tasso L
    Braz J Microbiol; 2020 Mar; 51(1):169-176. PubMed ID: 31845296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PK/PD modeling of daptomycin against MRSA and MRSE and Monte Carlo simulation for bacteremia treatment.
    Menezes B; Alves I; Staudt K; Beltrame B; Michelin L; de Araújo BV; Tasso L
    Braz J Microbiol; 2021 Dec; 52(4):1967-1979. PubMed ID: 34337679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.
    Woods RJ; Patel TS; Nagel JL; Newton DW; Read AF
    Infect Control Hosp Epidemiol; 2018 Feb; 39(2):226-228. PubMed ID: 29331166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacodynamics of Daptomycin against Enterococcus faecium and Enterococcus faecalis in the Murine Thigh Infection Model.
    Kidd JM; Abdelraouf K; Asempa TE; Humphries RM; Nicolau DP
    Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/Pharmacodynamic Analysis of Daptomycin Against Staphylococcus aureus and Enterococcus faecium in Pediatric Patients by Monte Carlo Simulation.
    Wei XC; Zhao MF; Li X; Xiao X
    J Clin Pharmacol; 2020 Jun; 60(6):768-774. PubMed ID: 32080861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia.
    Avery LM; Kuti JL; Weisser M; Egli A; Rybak MJ; Zasowski EJ; Arias CA; Contreras GA; Chong PP; Aitken SL; DiPippo AJ; Wang JT; Britt NS; Nicolau DP
    Int J Antimicrob Agents; 2019 Sep; 54(3):346-350. PubMed ID: 31284042
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.
    Avery LM; Kuti JL; Weisser M; Egli A; Rybak MJ; Zasowski EJ; Arias CA; Contreras GA; Chong PP; Aitken SL; DiPippo AJ; Wang JT; Britt NS; Nicolau DP
    Clin Infect Dis; 2019 May; 68(10):1650-1657. PubMed ID: 30188976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of daptomycin efficacy and breakpoint standards in a murine model of Enterococcus faecalis and Enterococcus faecium renal infection.
    Alder J; Li T; Yu D; Morton L; Silverman J; Zhang XX; Critchley I; Thorne G
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3561-6. PubMed ID: 14576118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
    Belley A; Arhin FF; Moeck G
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Daptomycin Dose on the Outcome of Vancomycin-Resistant, Daptomycin-Susceptible Enterococcus faecium Bacteremia.
    Chuang YC; Lin HY; Chen PY; Lin CY; Wang JT; Chen YC; Chang SC
    Clin Infect Dis; 2017 Apr; 64(8):1026-1034. PubMed ID: 28329222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
    Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
    J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.
    Carter GP; Harjani JR; Li L; Pitcher NP; Nong Y; Riley TV; Williamson DA; Stinear TP; Baell JB; Howden BP
    J Antimicrob Chemother; 2018 Jun; 73(6):1562-1569. PubMed ID: 29518208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daptomycin area under the curve to minimum inhibitory concentration ratio by broth microdilution for predicting the outcome of vancomycin-resistant Enterococcus bloodstream infection.
    Chuang YC; Lin HY; Wang JT; Yang JL; Lin CY; Huang SH; Chen YC; Chang SC
    Biomed Pharmacother; 2022 Nov; 155():113710. PubMed ID: 36156368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.
    Smith JR; Barber KE; Raut A; Aboutaleb M; Sakoulas G; Rybak MJ
    J Antimicrob Chemother; 2015; 70(6):1738-43. PubMed ID: 25645208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of Minimum Inhibitory Concentration in Clinical Outcomes of Enterococcus faecium Bacteremia Treated With Daptomycin: Is it Time to Change the Breakpoint?
    Shukla BS; Shelburne S; Reyes K; Kamboj M; Lewis JD; Rincon SL; Reyes J; Carvajal LP; Panesso D; Sifri CD; Zervos MJ; Pamer EG; Tran TT; Adachi J; Munita JM; Hasbun R; Arias CA
    Clin Infect Dis; 2016 Jun; 62(12):1514-1520. PubMed ID: 27045126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an
    Belley A; Lalonde-Séguin D; Arhin FF; Moeck G
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784674
    [TBL] [